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ABSTRACT
Background Parasympathetic pulmonary nerves release
acetylcholine that induces smooth muscle constriction.
Disruption of parasympathetic pulmonary nerves
improves lung function and COPD symptoms.
Aims To evaluate ‘targeted lung denervation’ (TLD),
a novel bronchoscopic therapy based on ablation of
parasympathetic pulmonary nerves surrounding the main
bronchi, as a potential therapy for COPD.
Methods This 1-year, prospective, multicentre study
evaluated TLD in patients with COPD forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) (FEV1/
FVC <0.70; FEV1 30%–60% predicted). Patients
underwent staged TLD at 20 watts (W) or 15 W
following baseline assessment off bronchodilators.
Assessments were repeated on tiotropium before
treatment and off bronchodilators at 30, 90, 180, 270
and 365 days after TLD. The primary endpoint was
freedom from documented and sustained worsening of
COPD directly attributable to TLD to 1 year. Secondary
endpoints included technical feasibility, change in
pulmonary function, exercise capacity, and quality of life.
Results Twenty-two patients were included (n=12 at
20 W, n=10 at 15 W). The procedures were technically
feasible 93% of the time. Primary safety endpoint was
achieved in 95%. Asymptomatic bronchial wall effects
were observed in 3 patients at 20 W. The clinical safety
proﬁles were similar between the two energy doses. At
1 year, changes from baseline in the 20 W dose
compared to the 15 W dose were: FEV1 (+11.6%±32.3
vs +0.02%±15.1, p=0.324), submaximal cycle
endurance (+6.8 min±12.8 vs 2.6 min±8.7, p=0.277),
and St George’s Respiratory Questionnaire (−11.1 points
±9.1 vs −0.9 points ±8.6, p=0.044).
Conclusions Bronchoscopic TLD, based on the concept
of ablating parasympathetic pulmonary nerves, was
feasible, safe, and well tolerated. Further investigation of
this novel therapy is warranted.
Trial registration number NCT01483534.
INTRODUCTION
Cholinergic parasympathetic nerves innervate both
large and small airways and provide the dominant
innervation to human lungs.1 Acetylcholine
released from these nerves regulates airway smooth
muscle tone, mucus secretion, and potentially local
inﬂammation through interaction with muscarinic
receptors found throughout the bronchial tree.2 3
Furthermore, pulmonary parasympathetic activity is
enhanced in COPD, and is the dominant reversible
component of airway obstruction in this disease.2
As such, disruption of parasympathetic activity in
the lungs is a logical, well characterised, and an
effective approach to the treatment of COPD.
Historically, parasympathetic nerve disruption via
surgical vagotomy has consistently demonstrated
the bronchodilator effect of vagotomy in
animals.4 5 Unfortunately, the majority of human
research of vagotomy as a treatment for COPD is
anecdotal or highly subjective.6 In one notable
study, surgical denervation of the lungs in 19
patients with intractable bronchial asthma increased
vital capacity from 2.36 L to 2.79 L, and maximal
voluntary ventilation from 43 L to 50 L/min.7
Sputum production was essentially stopped in eight
of the 11 patients with a previous history of heavy
sputum production.
In more recent history, pharmacologic blockade of
acetylcholine binding to muscarinic receptors has
been shown to produce bronchodilation and decrease
mucous production.8 One trial in COPD demon-
strated tiotropium to have a 9.6% improvement in
trough-forced expiratory volume in 1 s (FEV1) at
1 year accompanied by a −4.5-point change in St
George’s Respiratory Questionnaire (SGRQ).9 Similar
improvements in lung function and health-related
quality-of-life (HRQL) have been demonstrated by
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Key messages
What is the key question?
▸ Parasympathetic pulmonary nerves release
acetylcholine that causes smooth muscle
contraction and increased mucus production
contributing to airway obstruction and
symptoms in COPD. Is bronchoscopic
radiofrequency (RF) ablation of these
pulmonary nerves safe and feasible in patients
with mild to moderate COPD?
What is the bottom line?
▸ This ﬁrst-in-human study evaluated
bronchoscopic RF ablation of parasympathetic
pulmonary nerves running along the main
bronchi in patients with COPD. This approach is
shown to be feasible and safe.
Why read on?
▸ This new bronchoscopic therapy called
‘targeted lung denervation’, is a potential
future treatment option for patients with
advanced COPD.
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others.10 11 Tiotropium, when compared with placebo, also
improves cycle endurance time by 3.9 min, 2.5 h after inhalation,
and 2.9 min, 8 h after inhalation.12 A signiﬁcant focus on drug
development has resulted in numerous pharmaceutical therapies to
help manage COPD, and the majority of today’s treatment guide-
lines recommend anticholinergics as ﬁrst-line therapy for patients
with mild to advanced stages of COPD.13 14
Targeted lung denervation
Targeted lung denervation (TLD) is a novel bronchoscopic
therapy that ablates the parasympathetic innervation of the
lungs, and has a similar proposed mechanism of action to anti-
cholinergic drugs.2 TLD therapy is delivered via a dual-cooled
radiofrequency (RF) catheter (Holaira, Minneapolis, Minnesota,
USA) (ﬁgure 1) designed to target tissue heating at depth,
thereby producing a narrow band of ablation around the main
bronchi while minimising effects to the inner surface of the
airway. As RF current passes from the electrode through the
airway and surrounding tissues, these tissues are heated. Coolant
continuously circulated through the electrode and balloon
removes heat from the surface of the airway wall. The net effect
is targeted tissue ablation at depth with minimal heating and
damage of the inner surface of the airway.
This targeted tissue ablation is intended to disrupt motor
axons within bronchial nerve branches running along the
outside of the main bronchi, thereby blocking parasympathetic
signalling to the lungs and decreasing neuronal release of acetyl-
choline. This decrease in acetylcholine reduces airway obstruc-
tion in the whole lung by decreasing smooth muscle tone and
mucous production.
Extensive animal and human cadaver testing was undertaken
to develop the system and determine initial therapeutic RF
energy levels (unpublished data). This ﬁrst-in-human study was
designed to investigate the safety and feasibility of TLD therapy
in patients with moderate to severe COPD.
METHODS
Study design and participants
This non-randomised, prospective, sequential, two-dose study
was conducted at two sites in South Africa and one in The
Netherlands between 31 October 2011 and 21 November 2013.
Eligible patients were ≥40 years of age with COPD; deﬁned as
the ratio of the forced expiratory volume in 1 s (FEV1) to the
forced vital capacity (FVC) of ≤0.70 and postbronchodilator
FEV1 of 30%–60% of predicted normal values. Only patients
with a 15% or greater relative increase in FEV1 following inhal-
ation of 80 μg ipratropium bromide were included.
Figure 1 Description of the key components of the targeted lung
denervation (TLD) catheter.
Box 1 Protocol Inclusion and Exclusion Criteria
Inclusion criteria
▸ FEV1 30%–60%
▸ FEV1/ FVC <70%
▸ Patient is diagnosed with COPD (FEV1/ FVC <70%)
▸ Positive relative change in FEV1 >15% following
administration of ipratropium
▸ ≥40 years of age or older
▸ Smoking history of at least 10 pack years
▸ Non-smoking for a minimum of 6 months before consent and
agreed to continue not smoking for the duration of the study
▸ Patient has provided written informed consent
▸ The patient is willing, able and agrees to complete all
protocol-required baseline and follow-up assessments
including taking and abstaining from medications
▸ The patient has no child-bearing potential or a negative
pregnancy test
▸ Patient is a candidate for bronchoscopy in the opinion of the
physician or per hospital guidelines
▸ Current inﬂuenza vaccination and/or pneumococcus
vaccination consistent with local recommendations and/or
policy
Exclusion criteria
▸ Pulmonary hypertension, peripheral oedema suggesting CHF
or polycythaemia
▸ Patient has an SaO2 ≤ 88% or a PaO2 ≤ 7.3 kPa (55 mm Hg)
▸ Patient has a PaCO2 > 8.0 kPa (60 mm Hg)
▸ Previous lung transplant, LVRS, median sternotomy,
bullectomy or lobectomy
▸ Pulmonary nodule requiring surgery
▸ History of recurrent respiratory infections (>3 hospitalisations
within 1 year of consent)
▸ Presence of a pacemaker, internal deﬁbrillator or other
implantable electronic devices
▸ Active respiratory infection within the past 4 weeks
▸ COPD exacerbation within the past 4 weeks
▸ Myocardial infarction within the last 6 months
▸ Unstable or life-threatening arrhythmia within the last year
▸ Malignancy treated with radiation or chemotherapy within
the last 2 years
▸ Presence of other respiratory diseases (cystic ﬁbrosis,
tuberculosis, vocal cord dysfunction, Churg-Strauss
syndrome, allergic bronchopulmonary aspergillosis)
▸ Known hypersensitivity to anticholinergic drugs or
components
▸ Known allergy to medications required for bronchoscopy
(such as lidocaine, atropine) that cannot be medically
controlled
▸ Clinical diagnosis of sleep apnoea
▸ Clinical diagnosis of asthma or other respiratory disease
other than COPD
▸ Known coagulopathy
▸ Patient is taking clopidogrel, coumadin or other
blood-thinning medication
▸ The patient has any disease or condition that might interfere
with completion of this study (eg, life expectancy less than
1 year)
▸ Patient is currently enrolled in another clinical trial
CHF, congestive heart failure; LVRS, lung volume reduction
surgery; PaO2, partial pressure of oxygen; SaO2, saturation of
oxygen.
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Key exclusion criteria included: COPD exacerbation or active
respiratory infection within the past 4 weeks, more than 3
respiratory-related hospitalisations within 1 year of enrolment,
previous lung surgery, suspicious pulmonary nodule, pulmonary
hypertension, congestive heart failure, polycythaemia, SaO2
≤88% or a PaO2 ≤7.3 kPa, and PaCO2 >8.0 kPa. Formal pul-
monary rehabilitation was not a requirement for inclusion. Refer
to the box 1 for a full list of inclusion and exclusion criteria.
This study was approved by local ethics committees and in
accordance with the Declaration of Helsinki (1996), Good
Clinical Practice guidelines, and local requirements. An opera-
tions committee, and a data monitoring committee, oversaw
protocol management and safety for the study. An independent
clinical event reviewer adjudicated all serious adverse events
(SAE). This trial is registered with ClinicalTrials.gov, number
NCT01483534.
Study endpoints
The primary safety endpoint of freedom from documented and
sustained worsening of COPD directly attributable to the investi-
gational device or procedure to a 365-days post-TLD therapy,
was deﬁned as a decrease in the individual patient’s FEV1 by any
amount at all follow-up time points, along with a report of an
adverse event that was reported to have a probable or deﬁnite
relation to the device. Secondary endpoints included technical
feasibility of the device and change from baseline in pulmonary
function tests, exercise capacity assessments, and HRQL.
Technical feasibility was deﬁned as the ability to access the target
treatment area main bronchus and deliver RF energy to the entire
circumference of the bronchus at the target treatment site.
Procedures
After informed consent, patients underwent baseline testing after
a wash-out period of 8 days for long-acting muscarinic antago-
nists (LAMA), 24 h for long-acting β agonists (LABA) and 12 h
for short-acting β agonists (SABA) and short-acting muscarinic
antagonists (SAMA). Baseline and follow-up testing included
spirometry, body plethysmography, cycle ergometry, 6 min walk
test (6MWT), COPD-speciﬁc SGRQ (score range 0–100 with a
minimally clinically important difference (MCID) of ≥4 negative
units15), the Clinical COPD Questionnaire (CCQ, 7-day version,
score range 0–6, with an MCID of 0.4 units16), the common
Borg and modiﬁed Medical Research Council17 scales. Cycle
ergometry was ﬁrst conducted as an incremental maximal test to
determine baseline maximum work rate (Wmax) off drugs, and
subsequently as an endurance test conducted at a constant work
rate of 75% of the Wmax.
18 Current American Thoracic Society
(ATS)/European Respiratory Society (ERS) guidelines were
followed for pulmonary function testing,19 20 and ATS/American
College of Chest Physicians (ACCP) guidelines for cycle ergome-
try21 and the 6MWT.22 A baseline chest CT scan was required to
conﬁrm appropriate bronchial anatomy and rule out other pul-
monary abnormalities.
After completion of the wash-out baseline testing, patients
underwent a minimum 8-day run-in period while on tiotropium
bromide, and similar testing was performed at drug trough 24 h
after the last dose of tiotropium to establish tiotropium trough
baseline values. LABAs were again held for 24 h and SABAs and
SAMAs for 12 h before this testing. All patients underwent early
safety evaluation by phone at 3 days and 10 days postprocedure.
Testing was repeated at washout baseline, tiotropium trough
baseline, and 30, 90, 180, 270 and 365 days post-treatment,
except for cycle ergometry which was performed at 90, 180 and
365 days post-treatment. Patients were provided a daily memory
aid to track overall changes in health status. A total of three bron-
choscopies were performed per patient; two in order to complete
the two treatments and the third one to assess potential airway
surface effects during the 90-day follow-up visit. Adverse events
were tracked and recorded throughout the entire study period.
Treatment
Pretreatment visual bronchoscopic inspection of the airways was
conducted to reconﬁrm that appropriate airway anatomy existed.
Due to the construction of this ﬁrst-generation device, procedures
were performed via rigid bronchoscopy under general anaesthesia.
The dual-cooled catheter was placed through the rigid broncho-
scope, and a ﬂexible bronchoscope placed beside it for visualisa-
tion. The electrode was placed and activated in up to eight
rotational positions per bronchus to achieve complete circumfer-
ential treatment. Total balloon inﬂation times were approximately
3 min per activation. The initial subjects were treated with
20 watts (W) in all positions except for the posterior-medial
aspects of the left bronchus, where the power was reduced to
15W due to the proximity of the oesophagus in those positions.
Due to local airway effects, after a protocol amendment, add-
itional patients underwent treatment with a more distal placement
of the electrode along the medial wall to avoid the thin tissue of
the carina, and a lower 15 W energy level in all position.
Bronchoscopic and ﬂuoroscopic visualisation was used to guide
the electrode positioning (ﬁgure 2) throughout treatment. To
maximise safety, the protocol mandated staged treatment (2 thera-
peutic procedures per patient) with the second bronchus being
treated 30 days after the ﬁrst. No special post procedure medica-
tions were required, and the use of tiotropium was stopped.
Investigators were allowed to treat respiratory symptoms per
Figure 2 (A and B) ﬂuoroscopic view
(A) and bronchoscopic view (B) of the
electrode during the procedure. The
electrode is indicated by the arrow.
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standard-of-care and published guidelines, however, appropriate
drug wash-out was required before follow-up testing.
Statistical methods
As this was a feasibility study, there was no primary study
hypothesis with statistical inference. All p values were presented
for informational purposes. According to the prespeciﬁed ana-
lysis plan, continuous data were summarised using means and
SDs, or medians and quartiles, in the presence of non-normality.
Categorical data were tabulated, with counts and percentages.
All available data was summarised, with no imputation for
missing data. Final analyses were conducted using SAS V.9.3
(SAS Institute, Cary, North Carolina, USA) by an independent
statistical group (NAMSA, Minneapolis, Minnesota, USA).
Role of the funding source
The sponsor, D-JS, MM and CB designed the trial. Sites
recruited patients and collected data on standardised case report
Table 1 Baseline characteristics. Data are mean (SD) unless stated otherwise
20 W cohort (n=12) 15 W cohort (n=10) p Value
Age (years) 62.92 (11.37) 64.40 (8.87) 0.740
Male (n, %) 7 (58) 4 (40) 0.669
Ethnic origin (n, %)
White 12 (100) 8 (80) 0.195
Black 0 (0) 2 (20) –
History of smoking (n, %) 12 (100) 10 (100) –
Pack-years 38.57 (19.97) 44.60 (25.86) 0.544
Wash-out prebronchodilator FEV1 (L) 0.90 (0.28) 0.84 (0.15) 0.551
Wash-out prebronchodilator FVC (L) 2.56 (0.59) 2.45 (0.60) 0.664
Reversibility peak relative change in FEV1 (%) 25.95 (7.60) 19.89 (1.91) 0.019
Run-in tiotropium trough FEV1 (L) 1.04 (0.39) 0.98 (0.23) 0.651
Run-in tiotropium trough FVC (L) 2.89 (0.76) 2.75 (0.60) 0.661
Cycle endurance time @ 75% of max (min) 6.71 (3.26) 4.57 (2.20) 0.1059
SGRQ-C total score (points) 56.16 (13.71) 56.23 (20.85) 0.9931
Average diameter: right main bronchus (mm)* 13.42 (1.57) 13.91 (1.62) 0.519
Average diameter: left main bronchus (mm)* 12.02 (1.45) 12.33 (1.68) 0.672
*Measurements performed by the sponsor using Apollo Software (VIDA Diagnostics, Coralville, Iowa, USA).
FEV1 (L), expiratory volume in 1 s; FVC (L), forced vital capacity (FVC)
Figure 3 Clinical trial proﬁle and patient ﬂowchart.
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Bronchial perforation (carina) 2 (3) 2 (17) – – 2 (2) 2 (9)
Bronchial stenosis 1 (2) 1 (8) – – 1 (1) 1 (5)
Bronchial ulceration 1 (2) 1 (8) – – 1 (1) 1 (5)
COPD Exacerbation – – 1 (3) 1 (10) 1 (1) 1 (5)
Granulomas 1 (2) 1 (8) – – 1 (1) 1 (5)
Worsening of FEV1† – – 1 (3) 1 (10) 1 (1) 1 (5)
Device related-serious
Gastroparesis – – 1 (3) 1 (10) 1 (1) 1 (5)
Procedural related-non-serious (related or reported within 2 days of either procedure)
Broken tooth 1 (2) 1 (8) 1 (1) 1 (5)
Cough 2 (3) 2 (17) – – 2 (2) 2 (9)
Dyspnoea 2 (3) 2 (17) 1 (3) 1 (10) 3 (3) 3 (14)
Eczema – – 1 (3) 1 (10) 1 (1) 1 (5)
Headache 2 (3) 2 (17) – – 2 (2) 2 (9)
Mucus 3 (5) 3 (25) – – 3 (3) 3 (14)
Sore throat 3 (5) 3 (25) 1 (3) 1 (10) 4 (4) 4 (18)
Tracheal injury (due to rigid
bronchoscope)
1 (2) 1 (8) – – 1 (1) 1 (5)
Procedural related-serious (related or reported within 2 days of either procedure)
Anaphylactic reaction 1 (2) 1 (8) – – 1 (1) 1 (5)
COPD exacerbation – – 1 (3) 1 (10) 1 (1) 1 (5)
Other non-serious
Abscess (skin) – – 1 (3) 1 (10) 1 (1) 1 (5)
Back ache 1 (2) 1 (8) – – 1 (1) 1 (5)
Bronchitis – – 5 (13) 2 (20) 5 (5) 2 (9)
Candida – – 1 (3) 1 (10) 1 (1) 1 (5)
Chest pain 1 (2) 1 (8) – – 1 (1) 1 (5)
Common cold 2 (3) 2 (17) – – 2 (2) 2 (9)
COPD exacerbation 12 (20) 7 (58) 13 (33) 6 (60) 25 (25) 13 (59)
Cough 1 (2) 1 (8) – – 1 (1) 1 (5)
Diarrhoea 1 (2) 1 (8) – – 1 (1) 1 (5)
Difficulty swallowing 1 (2) 1 (8) – – 1 (1) 1 (5)
Dizziness 2 (3) 2 (17) 1 (3) 1 (10) 3 (3) 3 (14)
Dyspnoea 3 (5) 2 (17) 1 (3) 1 (10) 4 (4) 3 (14)
Flu 3 (5) 3 (25) 1 (3) 1 (10) 4 (4) 4 (18)
Gastritis 2 (3) 2 (17) 1 (3) 1 (10) 3 (3) 3 (14)
Gastroparesis 1 (2) 1 (8) – – 1 (1) 1 (5)
Pneumonia 1 (1) 1 (8) – – 1 (1) 1 (5)
Respiratory inflammation 4 (7) 4 (33) – – 4 (4) 4 (18)
Sinusitis – – 1 (3) 1 (10) 1 (1) 1 (5)
Other serious
Chest pain – – 1 (3) 1 (10) 1 (1) 1 (5)
COPD exacerbation 2 (3) 2 (17) 5 (13) 3 (30) 7 (7) 5 (23)
Coronary artery disease/CABG 1 (2) – – – 1 (1) 1 (5)
Flu – – 1 (3) 1 (10) 1 (1) 1 (5)
Lung infection 2 (3) 2 (17) – – 2 (2) 2 (9)
Stomach cancer (stage 3) – – 1 (3) 1 (10) 1 (1) 1 (5)
A total of 99 adverse events were reported in 22 (100%) subjects.
Serious/non-serious defined per ISO 14155.
All adverse events were independently adjudicated.
*Count reflects number of subjects with event reported one or more times.
†Adverse event included based on primary endpoint definition.
CABG, coronary artery bypass surgery; COPD, chronic obstructive pulmonary disease; RF, radiofrequency; SGRQ, St. George’s Respiratory Questionnaire.
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forms. The sponsor managed the overall study and safety
committees.
RESULTS
Twelve patients were included in the 20 W cohort, and an add-
itional 10 patients were included as part of the 15 W cohort at the
same sites using the same study criteria (ﬁgure 3). Demographic
and baseline characteristics were similar between the two cohorts,
with the 15 W cohort enrolling patients with slightly worse base-
line FEV1 (table 1). One-year follow-up data were available in
10 of 11 available patients in the 20 W cohort, and all 10 of the
15 W cohort. One patient in the 20 W cohort underwent coronary
bypass surgery for a calciﬁed coronary lesion during follow-up, and
was withdrawn from the study by the site investigator before the
Figure 4 Bronchoscopic conﬁrmation of airway healing after radiofrequency energy delivery: (A) Left main bronchus pretreatment. (B) During
treatment. (C) Immediately post-treatment. (D) 3-month follow-up.
Figure 5 CT and bronchoscopic ﬁndings seen before procedural enhancements: (A and B) A 4 mm granuloma indicated by white arrows on both
transverse CT and bronchoscopic images. (C and D) Superﬁcial airway effect indicated by white arrow on the bronchoscopic image with normal
transverse CT image. (E and F) A 1.5 mm perforation through carina indicated by white arrows on both coronal CT and bronchoscopic images.
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second procedure. One patient in the 15 W cohort experienced a
COPD exacerbation 10 days after the initial procedure and did not
consent to the 2nd treatment, but continued follow-up.
The primary safety endpoint was achieved in 100% (11/11)
in the 20 W cohort and 90% (9/10) in the 15 W cohort. The
one subject that failed to meet the endpoint had a decrease
from baseline in FEV1 at all follow-up time points, and a COPD
exacerbation 1 day after the 2nd treatment that was reported as
related to the lung denervation system and/or the bronchoscopy
by the investigator.
No deaths occurred in this study. Seven postprocedure SAEs
in the 30 days following treatment of either bronchus included
COPD exacerbation (n=3), anaphylactic drug reaction, coron-
ary artery bypass surgery, chest pain resulting in uneventful hos-
pitalisation, and gastroparesis in a subject with a history of
gastric issues. Four of these seven events occurred in a single
patient. Nine longer-term SAEs out to 1 year included COPD
exacerbation (n=5), pneumonia (n=2), inﬂuenza (H1N1)
(n=1), and stomach cancer (n=1). Events were evenly distribu-
ted between both cohorts, with the majority of events reported
during the periprocedural period (table 2).
The RF energy applied to the airway wall resulted in local
asymptomatic airway blanching, which resolved at the 3-month
follow-up bronchoscopy in all 10 of the 15 W patients, and in
eight of the 11 W–20 W patients with long-term follow-up
(ﬁgure 4). One patient had a superﬁcial tissue defect at the ﬁrst
treatment site seen at 30 days, without any airway abnormalities
on CT. A second patient had a small 1.5 mm perforation
through the thin tissue of the main carina, also discovered at
30 days. A third patient had a superﬁcial tissue defect at the
initial treatment site just distal to the main carina, as well as a
4 mm granuloma at the second treatment site, with a 20% sten-
osis observed during the follow-up bronchoscopy at 90 days
(ﬁgure 5). The granuloma was electively removed by cauterisa-
tion. No other treatments or interventions were performed, and
all showed complete or active healing during follow-up visual
inspection.
Technical feasibility was 93%, with 39 of 42 procedures deli-
vering full circumferential treatment (up to eight individual acti-
vations) to the target treatment site of the main bronchus. Two
patients had only one bronchus treated as outlined above. Three
patients had incomplete (non-circumferential) treatment: two
had airway geometries that limited electrode/balloon contact
with the right mainstem bronchus wall, and one had an intra-
procedural anaphylactic reaction to diclofenac that prohibited
full left bronchus treatment.
No device-related adverse events occurred during the proced-
ure. Mean (SD) procedure time (min) for the 20 W cohort was
47.75±8.13 for the right and 56.10±12.79 for the left bronchi.
Mean procedure time for the 15 W cohort was 42.10±8.23 for
the right and 51.33±25.76 for the left.
The results of FEV1 (% relative change), FVC, cycle ergometry
endurance and SGRQ at each time point assessed are shown in
ﬁgure 6. At the higher 20 W power level, signiﬁcant differences
from baseline were seen at the following assessment time points:
FVC at 90 days (p=0.016) and 270 days (p=0.036); cycle endur-
ance at 180 days (p=0.03), and SGRQ at 90 days (p=0.042),
180 days (p=0.019), 270 days (p=0.008) and 1 year (p=0.011).
Variability across time is noted, and most likely due to the small
sample size. No statistically signiﬁcant differences in any of the
variables measured were seen at the 15 W power level.
FEV1 per cent change from baseline at 1 year was 11.6±32.3%
vs 0.02±15.1% (p=0.324) in the 20 W and 15 W cohorts,
respectively (table 3). Similarly, FVC had a positive absolute posi-
tive change in FVC at 1 year of 198±516 mL in the 20 W cohort
vs 61±485 mL (p=0.256) in the 15 W cohort (ﬁgure 6).
Figure 6 Secondary efﬁcacy endpoints. Data represented as mean. Error bars represent SEM. *p <0.05 compared with baseline; FEV1: forced
expiratory volume in 1 s; Cycle Erg. Endurance, Cycle Ergometry Endurance; SGRQ, St. George’s Respiratory Questionnaire.
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Study results for exercise endurance and HRQL (ﬁgure 6)
show improvement from baseline for endurance cycle ergometry
was 6.8±12.8 vs 2.6±8.7 min (p=0.277) at 1 year. A signiﬁcant
difference was observed in HRQL as assessed by the SGRQ:
−11.1±9.1 vs −0.9±8.6 (p=0.044) in the 20 W and 15 W
cohorts, respectively.
At 90, 180 and 365 days, the effect on FEV1 of TLD therapy
plus 80 μg ipratropium bromide at peak was assessed. As illustrated
in ﬁgure 7, the combination therapy might result in an increase in
FEV1 over those seen with an inhaled anticholinergic drug alone.
Signiﬁcant differences between TLD +drug vs TLD alone were
seen at each matching time points assessed for both energy cohorts.
DISCUSSION
This ﬁrst-in-human clinical trial evaluated the novel TLD
therapy, designed to ablate the parasympathetic pulmonary
nerves surrounding the main bronchi, thereby decreasing
bronchomotor tone in patients with COPD. As a feasibility
evaluation, this study included a drug ‘wash-out’ period to
establish baseline values in order to understand the effect of this
new therapy alone. This study demonstrated TLD to be feasible,
safe and well tolerated. The primary endpoint was met in 95%
of patients, and technical feasibility was 93%. A tendency
toward improvements in lung function, exercise capacity, and
HRQL were observed in the 20 W cohort with statistical signiﬁ-
cance achieved for FVC at 90 days (p=0.016) and 270 days
(p=0.036); cycle endurance at 180 days (p=0.03) and SGRQ
at 90 days (p=0.042), 180 days (p=0.019), 270 days
(p=0.008) and 1 year (p=0.011). These improvements tended
to be larger than those seen in the 15 W cohort with statistically
signiﬁcant difference in SGRQ at 1 year (p=0.044).
Additionally, early data suggest an additive effect when TLD is
combined with inhaled anticholinergic drugs.
Three procedural adjustments were made during the study in
response to asymptomatic airway wall effects observed in three
of 12 patients in the 20 W group. These effects were postulated
to be attributable to a combination of energy delivery to the thin,
thermally sensitive tissue of the main carina, imperfect balloon
contact that limited surface cooling and, potentially, the higher
energy level. Subsequent computer modelling and bench testing
conﬁrmed heat accumulation in the thin tissue of the carina, and
post hoc analysis of procedural imaging indicated the balloon
was not able to accommodate itself to sharply tapering or sudden
geometric changes of the airway. As a result, the procedure was
modiﬁed to more distal electrode placement away from the main
carina, more detailed visual assessment of balloon contact before
activation, and decrease in overall power to 15 W to further
reduce the potential for undesired airway wall effects.










Baseline 851.0 (277.3) 836.0 (148.0) 843.5 (216.5) 0.882
1 year 900.0 (268.6) 835.0 (185.5) 867.5 (227.1) 0.537
Per cent Δ 11.6 (32.3) 0.02 (151) 5.8 (25.3) 0.324
FVC (mL)
Baseline 2439.0 (538.2) 2448.0 (602.9) 2443.5 (556.3) 0.972
1 year 2637.0 (802.2) 2509.0 (665.6) 2573.0 (720.4) 0.702
Per cent Δ 7.6 (21.9) 39 (19.1) 5.7 (20.1) 0.690
Total lung capacity (TLC)
Baseline 7.2 (1.2) 6.8 (1.2) 7.0 (1.2) 0.501
1 year 7.3 (1.8) 7.2 (1.2) 7.2 (1.5) 0.824
Per cent Δ 1.0 (11.8) 5.2 (9.6) 3.2 (10.6) 0.405
Residual volume (RV)
Baseline 4.6 (0.7) 4.1 (0.7) 44 (0.7) 0.164
1 year 4.6 (1.2) 4.4 (0.9) 4.5 (1.0) 0.696
Percent Δ 0.5 (21.2) 7.9 (20.6) 4.4 (20.6) 0.451
Inspiratory capacity (IC)
Baseline 1.8 (0.5) 1.7 (0.6) 1.8 (0.5) 0.885
1 year 1.7 (0.78) 1.8 (0.6) 1.8 (0.7) 0.743
Percent Δ −2.0 (31.6) 7.3 (22.0) 2.9 (26.6) 0.462
Pulmonary resistance (kPa×s/L)
Baseline 0.8 (0.3) 1.0 (0.2) 0.9 (0.2) 0.233
1 year 0.8 (0.2) 0.8 (0.1) 0.8 (0.2) 0.695
Percent Δ −4.6 (13.8) −19.1 (18.8) −12.2 (17.8) 0.074
Cycle ergometry endurance (min)
Baseline 5.8 (2.3) 4.2 (2.1) 5.1 (2.3) 0.139
1 year 12.7 (13.5) 6.9 (8.3) 10.1 (11.5) 0.301
Absolute Δ 6.8 (12.8) 2.6 (8.7 5.0 (11.1) 0.441
Borg scale: post-testing (cycle ergometry): dyspnoea
Baseline 4.4 (1.6) 6.1 (1.3) 5.2 (1.7) 0.023
1 year 4.1 (2.0) 5.3 (1.8) 4.6 (1.9) 0.223
Absolute Δ −0.3 (2.0) −0.9 (2.0) −0.6 (2.0) 0.556
mMRC scale
Baseline 1.0 (1.3) 1.2 (1.1) 1.1 (1.1) 0.788
1 year 0.3 (0.5) 1.8 (1.3) 1.0 (1.2) 0.031
Absolute Δ −0.7 (0.8) 0.6 (1.3) −0.1 (1.2) 0.085
6 min walk test (metres)
Baseline 388.1 (82.8) 425.4 (74.7) 406.8 (79.1) 0.304
1 year 412.3 (51.7) 416.1 (120.0 414.2 (89.9) 0.928
Absolute Δ 24.2 (45.6) −9.3 (70.6) 7.5 (60.4) 0.224
SGRQ-C: total score
Baseline 53.2 (14.1) 57.9 (17.9) 55.4 (15.6) 0.575
1 year 42.1 (12.) 57.1 (21.8) 49.1 (18.4) 0.120
Absolute Δ −11.1 (9.1) −0.9 (8.6) −6.3 (10.1) 0.045
CCQ: total score
Baseline 2.8 (1.0) 2.63 (1.0) 2.7 (1.0) 0.732
1 year 2.2 (1.0) 2.77 (1.0) 2.4 (1.0) 0.230
Absolute Δ −0.6 (0.8) 0.14 (0.7) −0.3 (0.8) 0.051
Data are mean (SD) unless stated otherwise.
SGRQ, St. George’s Respiratory Questionnaire (COPD specific); CCQ, clinical COPD
questionnaire; mMRC, Modified Medical Research Council dyspnoea scale.
p Values are for comparisons between cohorts.
Figure 7 Efﬁcacy measures of targeted lung denervation (TLD)
therapy +inhaled ipratropium bromide. Data represented as mean. Error
bars represent SEM. *p<0.05 compared with baseline. Follow-up data
points were compared with results of TLD alone, and all were
statistically signiﬁcant.
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In this study, the 12 patients treated with 20 W tended to
have greater changes from baseline in spirometry, exercise cap-
acity and HRQL, when compared with the 10 patients treated
with 15 W. The added effect in the 20 W group might be attrib-
utable to more effective denervation due to a deeper tissue
effect at higher energy. On the other hand, the 20 W group
patients were slightly more reversible to ipratropium at baseline,
which theoretically, might mean that these patients are more
sensitive to TLD therapy. However, we found no difference
between the two groups in tiotropium through FEV1 levels.
Apart from the airway effects observed, safety proﬁles for the
two energy levels were similar. This might imply that future
catheter designs that better accommodate human airway irregu-
larities will ensure better surface cooling and, thus, allow higher
energy levels to be used.
In this paper, we introduced TLD, a novel bronchoscopic
treatment concept for symptomatic patients suffering from
COPD. Based on the concept of ablating parasympathetic pul-
monary nerves, TLD was shown to be feasible, safe and well tol-
erated. TLD has the potential to overcome many of the
limitations of inhaled drugs for the treatment of COPD. First,
TLD may eliminate inhaler compliance issues for the 63% of
new tiotropium users who discontinue treatment after 1 year.23
Second, TLD would not be subject to the peak and trough var-
iations seen with drugs.24 Third, TLD may eliminate variable
regional drug delivery and deposition in patients with obstruct-
ive lung disease25 by ablating the nerves that travel throughout
the bronchial tree independent of regional airﬂow obstruction.
Fourth, by interfering with parasympathetic nerve-derived
acetylcholine by two different mechanisms, the combination of
TLD +inhaled anticholinergic drugs, as suggested in ﬁgure 7,
may have a synergistic effect that results in a reduction in airway
obstruction and mucus production, as well as inhibition of local
airway inﬂammation induced by non-neural muscarinic
action.8 26 Further investigation and progressive product devel-
opment of this novel therapy is warranted, with focus on
further reﬁning energy delivery to ablate the nerves and opti-
mise patient selection.
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